BioTime Inc

Find Ratings Reports
BTX : AMEX : Health Care
$3.19 | %
Today's Range: 3.12 - 3.35
Avg. Daily Volume: 378500.0
03/24/17 - 4:00 PM ET

Financial Analysis


BIOTIME INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. BIOTIME INC is extremely liquid. Currently, the Quick Ratio is 2.70 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 338.54% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)1.081.46
EBITDA ($mil)0.0-20.08
EBIT ($mil)-11.25-21.7
Net Income ($mil)-5.08-13.42


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)22.7242.98
Total Assets ($mil)142.5794.66
Total Debt ($mil)2.60.7
Equity ($mil)117.9326.89


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin-1039.06-1374.67
EBITDA Margin0.0-1374.67
Operating Margin-1039.06-1485.28
Sales Turnover0.040.07
Return on Assets23.54-49.64
Return on Equity28.46-176.28
Debt Q4 FY16 Q4 FY15
Current Ratio2.93.79
Debt/Capital0.020.03
Interest Expense0.230.0
Interest Coverage-48.090.0


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)102.7890.42
Div / share0.00.0
EPS-0.05-0.16
Book value / share1.150.3
Institutional Own % n/a n/a
Avg Daily Volume356344.0260827.0

Valuation


HOLD. BIOTIME INC's P/E ratio indicates a significant discount compared to an average of 40.94 for the Biotechnology industry and a significant discount compared to the S&P 500 average of 26.73. To use another comparison, its price-to-book ratio of 2.70 indicates valuation on par with the S&P 500 average of 2.98 and a significant discount versus the industry average of 13.45. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, BIOTIME INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BTX 9.69 Peers 40.94   BTX NA Peers 23.70

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

BTX is trading at a significant discount to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BTX NM Peers 60.14   BTX NM Peers 0.53

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

BTX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

BTX's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BTX 2.70 Peers 13.45   BTX 154.23 Peers 169.46

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BTX is trading at a significant discount to its peers.

 

Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

BTX is expected to keep pace with its peers on the basis of earnings growth.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BTX 53.82 Peers 295.21   BTX -15.82 Peers 518.87

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BTX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BTX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades